| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803136501018 | 313650101 | TADALAFIL/ARITI F.C.TAB 2.5MG/TAB BTx28 CAPS σε Blister (PVC-PVDC/Al) | 38.74 | 40.83 | 58.43 |
| 05/2018 | 2803136502022 | 313650202 | TADALAFIL/ARITI F.C.TAB 5MG/TAB BTx28 CAPS σε Blister (PVC-PVDC/Al) | 37.53 | 39.56 | 56.61 |
| 05/2018 | 2803136503012 | 313650301 | TADALAFIL/ARITI F.C.TAB 10MG/TAB BTx4 CAPS σε Blister (PVC-PVDC/Al) | 17.00 | 17.92 | 25.64 |
| 05/2018 | 2803136504026 | 313650402 | TADALAFIL/ARITI F.C.TAB 20MG/TAB BTx4 CAPS σε Blister (PVC-PVDC/Al) | 17.57 | 18.52 | 26.50 |
Used for the treatment of erectile dysfunction.
Tadalafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by tadalafil enhances erectile function by increasing the amount of cGMP.
Oral, Rat LD<sub>50</sub> = 2000 mg/kg, no deaths or toxicity.
After single oral-dose administration, the maximum observed plasma concentration (Cmax) of tadalafil is achieved between 30 minutes and 6 hours (median time of 2 hours). Absolute bioavailability of tadalafil following oral dosing has not been determined.
17.5 hours
Tadalafil is excreted predominantly as metabolites, mainly in the feces (approximately 61% of the dose) and to a lesser extent in the urine (approximately 36% of the dose).
* 63 L
* oral cl=2.5 L/hr